Skip to main content

#Coronavirus Disease Research #References (by AMEDEO, October 11 '25)

Image
By G.M.

 


    Antiviral Res

  1. SCHRELL L, Scheibner D, Dickmanns A, Stegmann KM, et al
    Inhibitors of pyrimidine synthesis synergize with N4-hydroxycytidine to diminish influenza virus replication.
    Antiviral Res. 2025 Oct 3:106286. doi: 10.1016/j.antiviral.2025.106286.
    PubMed         Abstract available


    BMJ

  2. WISE J
    Covid-19: Excluding doctors from vaccination programme puts patients at risk, clinicians warn.
    BMJ. 2025;391:r2141.
    PubMed        


    Clin Infect Dis

  3. ATMAR RL, Abate G, Deming ME, George SL, et al
    Emerging and Pandemic Pathogens: Lessons Learned From a Clinical Research Network.
    Clin Infect Dis. 2025;81.
    PubMed         Abstract available

  4. JANO K, Babu TM, Kottkamp AC, Rebolledo PA, et al
    Historical Advances in Clinical Trial Design and Expanding Representation as the New Frontier for Innovation.
    Clin Infect Dis. 2025;81.
    PubMed         Abstract available

  5. BELSHE RB, Bernstein DI, Edwards KM, Frey SE, et al
    Vaccine and Treatment Evaluation Units: A Historical Perspective.
    Clin Infect Dis. 2025;81.
    PubMed         Abstract available


    Int J Infect Dis

  6. WAN EYF, Choi MH, Wang B, Xu Y, et al
    Comparative Effectiveness of Combination Therapy with Nirmatrelvir-Ritonavir and Molnupiravir versus Monotherapy with Molnupiravir or Nirmatrelvir-Ritonavir in Hospitalised COVID-19 Patients: A Target Trial Emulation Study.
    Int J Infect Dis. 2025 Oct 3:108097. doi: 10.1016/j.ijid.2025.108097.
    PubMed         Abstract available

  7. KIM JA, Park S, Cho H, Jeong NY, et al
    Sex Differences in Adverse Event Reporting Rates Following COVID-19 Vaccination in South Korea During the Pandemic.
    Int J Infect Dis. 2025 Oct 6:108107. doi: 10.1016/j.ijid.2025.108107.
    PubMed         Abstract available

  8. FARINAS RP, Alonso-Sardon M, Solis P, Alonso BR, et al
    The impact of the SARS-CoV-2 pandemic on the development of respiratory infections caused by Aspergillus spp., Mucor spp., and Pneumocystis jirovecii within the National Health System of Spain.
    Int J Infect Dis. 2025 Oct 7:108101. doi: 10.1016/j.ijid.2025.108101.
    PubMed         Abstract available

  9. LI Y, Sun C, Zhao T, Ni Y, et al
    Etiology of Initial Treatment Failure in Non-immunosuppressed Adult Patients with Community-acquired Pneumonia.
    Int J Infect Dis. 2025 Oct 8:108110. doi: 10.1016/j.ijid.2025.108110.
    PubMed         Abstract available

  10. SONG JY, Choi WS, Heo JY, Kim YR, et al
    Safety and immunogenicity of a homologous booster dose of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: 12 months follow-up result of an open-label, non-randomised extension of a phase 1/2 trial.
    Int J Infect Dis. 2025 Oct 8:108108. doi: 10.1016/j.ijid.2025.108108.
    PubMed         Abstract available


    J Infect

  11. FOULKES S, Munro K, Sparkes D, Khawam J, et al
    Prevalence and impact of SARS-CoV-2, influenza, respiratory syncytial virus (RSV) infection and respiratory illness on UK healthcare workers during winter 2023/24 (September 2023 to March 2024): SIREN cohort study.
    J Infect. 2025;91:106620.
    PubMed         Abstract available


    J Med Virol

  12. TIAN Y, Zhou Y, Wang Q, Li X, et al
    Proteomic and Phosphoproteomic Profiling of Kidney in Rhesus Macaques With SARS-CoV-2 Infection.
    J Med Virol. 2025;97:e70633.
    PubMed         Abstract available

  13. PASITTUNGKUL S, Thongpan I, Thongmee T, Thatsanathorn T, et al
    Longitudinal RSV Antibody Trends in Thai Children (0-8 Years): Association With Seasonal Outbreak Patterns and Potential Immunity Debt During the COVID-19 Pandemic.
    J Med Virol. 2025;97:e70629.
    PubMed         Abstract available


    J Virol

  14. ZAIB W, Kaviani C, Kang X, Gao Y, et al
    Porcine hemagglutinating encephalomyelitis virus VW572 (not Gent/PS412 and Labadie) uses the CD81 receptor and MVB-derived exosomal pathway for efficient entry and spread in neuronal cells.
    J Virol. 2025 Oct 8:e0117125. doi: 10.1128/jvi.01171.
    PubMed         Abstract available

  15. PERRY JK, Itskanov S, Bilello JP, Lansdon EB, et al
    A structural roadmap for the formation of the coronavirus nsp3/nsp4 double membrane vesicle pore and its implications for polyprotein processing and replication/transcription.
    J Virol. 2025 Oct 8:e0145725. doi: 10.1128/jvi.01457.
    PubMed         Abstract available

  16. MITCHELL JK, Mastrodomenico V, Hartnett J, Heelan WJ, et al
    A HiBiT-tagged pseudovirus-like particle platform for safe, rapid quantification of virus neutralization and antibody-dependent enhancement.
    J Virol. 2025 Oct 8:e0099125. doi: 10.1128/jvi.00991.
    PubMed         Abstract available

  17. WANG W, Du P, Zhao Y, Liang Y, et al
    Biomimetic nanovaccines with self-adjuvant effects induced broad-spectrum neutralizing antibodies against SARS-CoV-2 infection in rodents.
    J Virol. 2025 Oct 10:e0031525. doi: 10.1128/jvi.00315.
    PubMed         Abstract available


    JAMA

  18. SHAH J
    Through the Glass.
    JAMA. 2025 Oct 9. doi: 10.1001/jama.2025.18165.
    PubMed        

  19. ANDERER S
    COVID-19 Linked to Lasting and Underrecognized Smell Impairment.
    JAMA. 2025 Oct 10. doi: 10.1001/jama.2025.17491.
    PubMed        


    N Engl J Med

  20. CAI M, Xie Y, Al-Aly Z
    Association of 2024-2025 Covid-19 Vaccine with Covid-19 Outcomes in U.S. Veterans.
    N Engl J Med. 2025 Oct 8. doi: 10.1056/NEJMoa2510226.
    PubMed         Abstract available


    Nat Ment Health

  21. KESSLER RC, Millikan-Bell AM, Edwards ER, Gildea SM, et al
    Effects of exposure to pandemic-related stressors on anxiety and mood difficulty during versus before the COVID-19 pandemic in United States Army soldiers and veterans.
    Nat Ment Health. 2025 Sep 29:10.1038/s44220-025-00505.
    PubMed         Abstract available


    Zhonghua Jie He He Hu Xi Za Zhi

  22. WANG MC, Liu X, Hu K
    [Intermittent hypoxia exposure in the rehabilitation of long COVID patients].
    Zhonghua Jie He He Hu Xi Za Zhi. 2025;48:961-964.
    PubMed         Abstract available
Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

By G.M.
Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...
Post a Comment
Read more »

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

By G.M.
Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...
Post a Comment
Read more »